Open AccessIs there a role for phosphodiesterase type-5 inhibitors in the treatment of premature ejaculation?
Author(s) -
Antônio Aversa,
Davide Francomano,
Roberto Bruzziches,
M. Natali,
Giovanni Spera,
Andrea Lenzi
Publication year - 2011
Publication title -
international journal of impotence research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.508
H-Index - 84
eISSN - 1476-5489
pISSN - 0955-9930
DOI - 10.1038/ijir.2010.34
Subject(s) - premature ejaculation , medicine , cgmp specific phosphodiesterase type 5 , ejaculation , sexual dysfunction , clinical efficacy , erectile dysfunction , psychology , psychoanalysis
Premature ejaculation (PE) is considered to be the most common male sexual dysfunction. The realization that PE may co-exist with ED prompted the use of PDE5-i's alone or in combination with selective serotonin reuptake inhibitors (SSRIs) for treating ejaculatory disorders. Until recently, there was little evidence that PDE5-i's alone may have a role in the treatment of PE in the absence of ED, and current available treatments include only on-demand dapoxetine. However, available data indicate that there is clinical, anatomical, physiological, pharmacological and genetic evidence to explain the efficacy of PDE5-i's. Nine manuscripts that examined the efficacy of PDE5-i's in the treatment of PE, alone or in combination with SSRIs, were retrieved. All studies reported some significant changes in the intravaginal ejaculatory latency time and sexual satisfaction scores, although not all were clinically meaningful. Well-designed multicenter studies are urgently required to further elucidate the efficacy and safety, as well as the mechanisms of action of PDE5-i's in the treatment of PE. The aim of this review is to discuss basic rationale and to show clinical evidence sustaining the possibility to use off-label PDE5-i's to treat PE.